Harbour BioMed launches new obesity biotech on mission to preserve muscle mass
China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen obesity meds—reducing body weight without losing muscle mass.
China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen obesity meds—reducing body weight without losing muscle mass.
